Alzheimer's Disease

Early diagnosis of Alzheimer‘s disease is quite important to disclose preclinical healing alterations, It also helps identifying the progress of the disease and to make changes in the treatment. The examination of cerebral glucose metabolism using 18 F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) plays a significant role in the early detection of Alzheimer's disease, as the decline in cerebral glucose metabolism occurs well in advance of the attack of AD symptoms.

This approach employs both qualitative and quantitative assessments of cerebral glucose metabolism to achieve heightened sensitivity in the early detection of Alzheimer's disease. Moreover, FDG-PET imaging holds promise for identifying persons who are at an elevated possibility of developing Alzheimer's disorder. within populations with mild cognitive impairment. However, its specificity is limited because decreased cerebral glucose metabolism is a common finding in various types of dementia.

Nonetheless, early-stage Alzheimer's patients typically exhibit diminished metabolism in the middle material lobes and parieto-temporal posterior cortices, with further cortical involvement in later stages. Integrating FDG-PET accompanying other biomarkers to a degree, cerebrospinal fluid flags, and amyloid plaque depict tracers could enhance preclinical diagnostic veracity and offer hopeful avenues for assessing individual forecast in Alzheimer's disease